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p120 RasGTPase-activating protein (RasGAP), the main
regulator of Ras GTPase family members, is cleaved at low
caspase activity into an N-terminal fragment that triggers
potent anti-apoptotic signals via activation of the Ras/PI-3
kinase/Akt pathway. When caspase activity is increased,
RasGAP fragment N is further processed into two frag-
ments that effectively potentiate apoptosis. Expression of
RasGAP protein and its cleavage was assessed in human
lung cancer cells with different histology and responsive-
ness to anticancer drug-induced apoptosis. Here we show
that therapy-sensitive small lung carcinoma cell (SCLC)
lines have lower RasGAP expression levels and higher
spontaneous cleavage with formation of fragment N com-
pared to therapy-resistant non-small cell lung carcinoma
cell (NSCLC) lines. The first RasGAP cleavage event
strongly correlated with the increased level of spontaneous
apoptosis in SCLC. However, generation of protective Ras-
GAP fragment N also related to the potency of SCLC to
develop secondary therapy-resistance. In response to eto-
poside (ET), RasGAP fragment N was further cleaved in
direct dependence on caspase-3 activity, which was more
pronounced in NSCLC cells. Caspase inhibition, while
effectively preventing the second cleavage of RasGAP,
barely affected the first cleavage of RasGAP into fragment
N that was always detectable in NSCLC and SCLC cells.
These findings suggest that different levels of RasGAP and
fragment N might play a significant role in the biology and
different clinical course of both subtypes of lung neo-
plasms. Furthermore, constitutive formation of RasGAP
fragment N can potentially contribute to primary resis-
tance of NSCLC to anticancer therapy by ET but also to
secondary therapy-resistance in SCLC.
Introduction
Lung carcinoma represents the leading cause of malignancy-
related mortality (1). Therefore, much attention has been given
to identify targets in the treatment of human lung cancer. One
of the most frequently used targets of drug classes is the
nuclear enzyme DNA topoisomerase II (2). Topoisomerases
are involved in several cellular events during the cell cycle
such as DNA replication, transcription, recombination and
chromatid segregation. Among the topoisomerase II-affecting
agents currently in clinical use is etoposide (ET). ET stabilizes
topoisomerase II-associated double-strand DNA breaks by inhib-
iting the enzyme ability to ligate cleaved nucleic acid mo-
lecules. However, ET does not only inhibit the cell cycle but
also affects other cellular functions. The ET targets are
referred to as pre-targets when they correspond to plasma
membrane and cytosolic components and to post-targets
when they participate in gene regulation. In this regard, cellu-
lar perturbation caused by ET is also realized via initiation of
apoptotic cell death (3). Proteolytic activation of a cascade of
caspases, a family of cysteine proteases that cleave their sub-
strates after aspartate residues, is considered as the central
element of the apoptotic machinery (4). The cascade is started
by auto-activation of initiator caspases, triggered either by
ligand binding to death domain receptors (extrinsic pathway)
or by cytosolic translocation of apoptogenic factors from mito-
chondria (intrinsic pathway). While the initiator caspase pro-
caspase-8 mediates the receptor-induced apoptosis, release of
cytochrome c from mitochondria leads to the activation of pro-
caspase-9 in an apoptosome complex thereby mediating the
mitochondrial-dependent pathway (5). The subsequent proteo-
lytic activation of executioner caspases, like pro-caspase-3, -6
and -7, results in the processing of a large variety of cellular
substrates. Those substrates are activated, deactivated or
acquire new functions once cleaved by caspases and contribute
to the characteristic morphological and biochemical changes
that occur during apoptosis (6).
However, caspase activation does not always result in the
proteolysis of cellular determinants participating in cell death.
Recently, it has been shown that p120 RasGTPase-activating
protein (RasGAP), the main down-regulator of Ras GTPase
family members (7), is a substrate for caspases that differen-
tially regulates apoptosis as caspase activity increases in cells
(8). Depending on the extent of its processing by caspases,
RasGAP fragments stimulate survival signals at low levels of
caspase activity but contribute to the execution phase of apop-
tosis when caspase activity is increased. The first cleavage of
RasGAP occurs at position 455 at very low caspase activity
(8). The resulting N-terminal fragment triggers potent
anti-apoptotic mechanisms while the C-terminal fragment,
containing the GTPase-binding function, leads to cell death
in Ras-independent manner (8). However, the anti-apoptotic
properties of fragment N are dominant over the pro-apoptotic
abilities of fragment C (8). The N-terminal fragment consists
mainly of Src homology (SH) domains, which have an import-
ant dynamic role in recruiting GAPs to specific signalling
complexes. Detailed investigation showed that RasGAP frag-
ment N is a potent inhibitor of apoptosis down-stream of
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caspase activation as shown for caspase-9 (8). Although frag-
ment N does not contain the GAP domain, it effectively pro-
tects cells by initiating the chain of protein reactions involved
in the Ras-mediated pathway. The homology domain SH3,
which is flanked by two SH2 domains, has been suggested to
be involved in this process (9). Subsequent activation of the
phosphatidylinositol (PI)-3 kinase results in the phosphoryla-
tion of target proteins that contain pleckstrin homology
domains for binding to the inner plasma membrane. In Ras-
GAP fragment N signalling, the serine/threonine kinase Akt
(also known as protein kinase B) has been shown to be an
effector of the PI-3 kinase pathway (10) via PDK1 (3-phospho-
inositide-dependent kinase)-mediated phosphorylation (11).
The PI-3 kinase-induced stimulation of Akt can contribute to
cell survival through a number of mechanisms. This includes
the inhibition of Bad activity (12) but also the suppression of
Bax translocation to mitochondria (13), blocking of pro-
caspase-9 activation (14) and stimulation of the transcription
factor NFkB activity via IkappaB kinase a (IKKa) (15). How-
ever, NFkB plays no role in the anti-apoptotic function of
fragment N (10). At higher levels of caspase activity, the
protective effect of RasGAP fragment N is abolished when
fragment N is cleaved at position 157. This second cleavage
event causes the formation of two N-terminal RasGAP frag-
ments, named N1 and N2, which can effectively potentiate
apoptotic cell death (8).
The aim of the present study was to investigate the expres-
sion and cleavage pattern of RasGAP in a panel of lung cancer
cell lines with different histology and sensitivity to anticancer
treatment. Human lung carcinomas are broadly classified into
non-small cell lung carcinomas (NSCLC) and small cell lung
carcinomas (SCLC). This simplified grouping is based on the
histology, biology and clinical behaviour of the tumours and
their treatment options (16). Both subtypes differ in their initial
responsiveness to chemotherapeutic agents including ET (17).
While chemotherapy provides rather poor response rates
in NSCLC patients with rare complete remissions, SCLC
belong to the most drug-sensitive tumours. SCLC accounts
for ~20--25% of all human lung cancers and, despite primary
chemo- and radiosensitivity, SCLC bears the poorest prognosis
of all lung cancer histologies due to fast tumour expansion,
early metastasis and high incidence of relapse along with the
subsequent development of therapy resistance (18). Therefore,
the resistance to treatment represents the major problem in the
therapy of NSCLC and SCLC as well. The poor responsive-
ness to topoisomerase II inhibitors might link to increased
expression of topoisomerase II, lowered drug accumulation
due to expression of membrane `pump' proteins, altered cyto-
toxic signalling through stress-activated protein kinases and
alterations in cell cycle proteins (19). Previously, it has been
shown that the different susceptibility of SCLC and NSCLC to
undergo apoptosis is related to the reduced drug response of
malignant lung neoplasm (20). While SCLC cells undergo cell
death in caspase-dependent and -independent manner, the
caspase-mediated pathway of apoptosis is inefficient in
NSCLC mainly because of a defective translocation of active
caspase-3 into the nucleus (21). While the reduced nuclear
localization of caspase-3 represents a key regulator of cell
death influencing the responsiveness to chemotherapeutic
agents in NSCLC, mechanisms involved in the acquired
chemoresistance in SCLC are not yet fully understood.
The PI-3 kinase/Akt pathway has been found to play a
significant role in the survival of experimental cancer cell
lines including NSCLC and SCLC (22,23). Furthermore,
altered expression of RasGAP is involved in tumorigenesis
as well (24) that might consequently lead to an impaired
controlling of p21 Ras signalling and other down-stream sig-
nalling pathways (7). Based on these observations and that
generation of the N-terminal RasGAP fragment participates
in survival mechanisms via PI-3 kinase/Akt, we were inter-
ested in analysing the level of RasGAP and its N-terminal
cleavage products in NSCLC and SCLC upon treatment of
lung cancer cell lines with ET in relation to caspase activity
and extent of apoptosis.
Material and methods
Antibodies and reagents
An antisera against the N-terminal moiety of RasGAP was produced in rabbits
injected with a fusion protein consisting of a stretch of 6 histidine linked to
amino acids 158--455 of RasGAP. This antigen was produced in BL21 (DE3)
pLysS bacteria (Novagen, Madison, MI) and purified by using a Ni--NTA
affinity column (Qiagen AG, Basel, Switzerland), as follows. Bacteria corre-
sponding to a 1 l culture were lysed and sonicated in 40 ml of lysis buffer
(50 mM HEPES, 500 mM NaCl, 10% Triton X-100, 20 mM Mg--acetate,
0.5% b-mercaptoethanol, proteases inhibitor cocktail from Roche Diagnostics
(Mannheim, Germany), 2 mg/ml lysozyme, ~25 mg/ml DNase I). The bacterial
lysate was incubated for 45 min at 4C with 1 ml of Ni--NTA beads, washed
three times with 1 ml of lysis buffer containing 25 mM imidazole. The antigen
was then eluted with 600 ml of lysis buffer containing 200 mM imidazole. The
eluate was dialysed two times against 5 l phosphate-buffered saline (PBS) to
remove imidazole and kept at ÿ80C until further use. Antibodies specific for
RasGAP were further purified as follows. Three millilitres of the antisera
diluted 10 times in 10 mM Tris--HCl (pH 7.5) were loaded three times on
a column containing 300 ml of Affigel 15 beads (Bio-Rad Laboratories,
Hercules, CA) on which 1.5 mg of the antigen was coupled covalently. The
beads were washed with 6 ml 500 mM NaCl, 10 mM Tris--HCl (pH 7.5) and
6 ml 10 mM Tris--HCl (pH 7.5). The antibody against RasGAP was eluted by
using 3 ml of 100 mM glycine (pH 2.5) and recovered in 300 ml of 1 M
Tris--HCl (pH 8.0). The antibody was stored at ÿ20C until use. The antibody
directed to the C-terminal moiety of RasGAP was from Alexis (ALX-210-781;
Lausanne, Switzerland). Rabbit polyclonal antibodies against caspase-3, -8 and
-9, or mouse monoclonal antibodies against cytochrome c and poly(ADP-
ribose) polymerase (PARP) (all are from BD Pharmingen, San Diego, CA)
were applied in PBS-T buffer (10 mM Na2HPO4, 140 mM NaCl, 0.15% Tween
20; pH 7.35). Equal protein loading was controlled by using the polyclonal
antibody against glyceraldehydes-3-phosphate dehydrogenase (GAPDH;
Trevigen, Gaithersburg, MD). Bound antibodies were detected by horseradish
peroxidase-conjugated goat anti-rabbit IgG or goat anti-mouse IgG antibodies
(Pierce, Rockford, IL), respectively, which were diluted in PBS-T supplemen-
ted with 2% non-fat dry milk.
Lung cancer cells were treated with ET (VepesidÒ, VP16; Bristol-Myers
Squibb, Bromma, Sweden), staurosporine (ST) (Roche Diagnostics) or the
agonistic aFas monoclonal antibody (SY-001; Medical & Biological Labor-
atories, Nagoya, Japan) to induce cell death. The cell permeable peptide
zVAD-FMK was applied as pan-caspase irreversible inhibitor, zDEVD-FMK
for inhibiting caspase-3/-7 and zIETD-FMK for caspase-8 activities, respec-
tively (all are from Enzyme Systems Products, Livermore, CA). The fluoro-
genic substrates Ac-DEVD-AMC and Ac-LEHD-AMC (Peptide Institute Inc.,
Osaka, Japan) were used for the determination of proteolytic caspase activities.
Cell lines, culture conditions and treatment
Human cell lines that were analysed correspond to NSCLC (A549, H23, H125,
H157, H661, U1752 and U1810) or to SCLC (H69, H82, H592, U1285, U1690
and U1285dox, a doxorubicin-resistant variant of U1285). All cell lines of
H denotation have the prefix National Cancer Institute (NCI). Additionally,
HeLa cells (human cervix carcinoma) and Jurkat cells (human T cell leukemia)
were investigated as a non-lung cancer control. Lung cancer cell lines of
U denotation are characterized earlier (25), cell lines of A or H denotation,
HeLa and Jurkat (TIB 152) are purchased from the ATCC cell bank (Manassas,
VA). Cells were cultured in RPMI 1640 medium supplemented with 7.5%
heat-inactivated foetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin
and 100 mg/ml streptomycin (Invitrogen Life Technology, Taby, Sweden) in
5% CO2 atmosphere at 37
C.
Twenty-four hours after seeding in culture dishes with fresh medium, cells
were treated by adding ET (2.5--10 mM, 48 h), ST (1 mM, 2--6 h) or the
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agonistic aFas monoclonal antibody (200 ng/ml, 24 h). Mock-treated cells of
long-term experiments were seeded initially at less density to keep control cells
at levels allowing exponential growth. The caspase inhibitory peptides zVAD-
FMK, zDEVD-FMK and zIETD-FMK were used at 20 mM final concentration
and added 1 h prior to treatment.
Cell death analysis
Apoptosis was analysed by investigation of nuclear alterations. An aliquot of
the cells was re-suspended in PBS, spread on slides and allowed to air-dry.
After fixation with acetone and staining with 1 mg/ml Hoechst 33342 in PBS
(Molecular Probes Europe, Leiden, The Netherlands), 400 cells were assessed
in each sample and scored as percentage of cells with fragmented and con-
densed nuclear morphology. In situ nuclear DNA fragmentation was deter-
mined by terminal deoxynucleotidyltransferase (TdT)-mediated dUTP nick
end-labelling (TUNEL). Cells were prepared on slides, fixed with 3.7%
paraformaldehyde (pH 7.4) and permeabilized with 0.1% Triton X-100 in PBS.
After blocking with 3% bovine serum albumin in PBS and pre-incubation in
TdT reaction buffer (pH 6.6), TUNEL reaction was carried out in a humidified
chamber with 5 mM Fluorescein-12-dUTP, 50 mM dATP, 2.5 mM CoCl2 and
25 U TdT (Roche Diagnostics) in TdT buffer at 37C for 1 h. Thereafter, slides
were co-stained with Hoechst 33342 in PBS and mounted with 50% glycerol
in PBS. Samples were examined with an Olympus BX60 fluorescence micro-
scope (excitation wavelength 365 nm) and images collected using the
Hamamatsu digital camera ORCA II.
SubG1 DNA content was quantified by staining of DNA with propidium
iodide (PI; Sigma, Deisenhofen, Germany) and subsequent flow cytometry.
Briefly, PBS-rinsed cells were fixed with ice-cold 70% ethanol and incubated
with PI solution (50 mg/ml PI, 5 mg RNase A, 0.1% Triton X-100,
0.1% sodium citrate, 0.1 mM Na2EDTA in PBS; pH 7.2) for 1 h at 4
C.
DNA content was measured using the FACScan flow cytometer equipped
with Cell Quest software (Becton Dickinson, San Jose, CA). Additionally,
amount of cells with loss of the plasma membrane integrity was counted in a
haemacytometer after viability staining with 0.2% trypan blue in PBS. Another
hallmark of cell death, the release of cytochrome c from mitochondria, has
been quantified by immunoblot analysis of cytosolic protein preparations (see
below).
In vitro caspase assay
Caspase activity was measured by cleavage of fluorogenic substrates specific
for caspase-3-like proteases (Ac-DEVD-AMC) and caspase-9 (Ac-LEHD-
AMC). Briefly, 2.5  105 cells were seeded initially. After treatment, cells
were re-suspended in 30 ml PBS and 25 ml were transferred to a 96-well plate.
The remaining cell aliquot was kept for protein determination using the BCA
protein assay (Pierce, Rockford, IL). Enzyme reaction was performed at 37C
by adding 50 ml of either HEPES buffer (100 mM HEPES, 10% sucrose,
0.1% CHAPS, 5 mM DTT, 10ÿ6% NP-40; pH 7.25) for caspase-3/-7 or MES
buffer (100 mM MES, 10% sucrose, 0.1% CHAPS, 5 mM DTT, 10ÿ6% NP-40;
pH 6.5) for caspase-9 containing 30 mM of the respective peptide substrate.
AMC liberation was monitored by a Fluoroscan II plate reader (Labsystems,
Stockholm, Sweden) at 355 nm excitation and 460 nm emission, finally con-
verted to pmol of AMC release per min and normalized per mg protein.
Protein extraction and immunoblot analysis
For preparation of cytosolic protein fraction, samples were incubated in isola-
tion buffer (20 mM HEPES, 10 mM NaCl, 120 mM KCl, 1 mM KH2PO4,
1 mM MgCl2, 250 mM sucrose, 2 mM Na2ATP; pH 7.2) containing 10 mg
digitonin per 1 106 cells and protease inhibitor cocktail (Roche Diagnostics).
After 5 min of incubation at room temperature, lysates were cleared by
centrifugation at 15 000 g for 10 min. In the case of total protein extraction,
1% Triton X-100 was added to the isolation buffer. Protein concentration was
measured by the BCA protein assay (Pierce). All protein samples were mixed
with 4 loading buffer (500 mM Tris--HCl, 40% glycerol, 8% SDS, 80 mM
DTT, 4 mM Na2EDTA, 0.2% bromophenol blue; pH 7.4), boiled for 2 min and
separated using SDS--PAGE. Proteins of the analytic gel were blotted onto a
nitrocellulose membrane in 10 mM CAPS buffer/20% methanol (pH 11.0) by
the Bio-Rad wet blotting system (Bio-Rad Laboratories, Sundbyberg,
Sweden). Thereafter, the membrane was blocked with 6% non-fat dry milk
in PBS-T and incubated with the respective antibody. Primary antibodies were
detected by horseradish peroxidase-conjugated secondary antibodies and
subsequently visualized by the ECLplus substrate solution (Amersham,
Buckinghamshire, UK) according to manufacturer's instruction. The intensity
of visualized signals was densitometrically analysed using the Aida evaluation
software (Raytest, Straubenhardt, Germany).
Statistics
The significance of comparison of mean values was determined by the
Student's t test. The one-way ANOVA procedure or the ANOVA analysis on
Ranks for non-parametric groups was used for multiple comparisons. The
correlation coefficient r of the linear regression analysis was tested using the
two-sided test (SigmaStat software; Jandel, San Rafael, CA). All data reported
are given as mean SEM with P5 0.05 as indicating a significant difference.
Results
RasGAP expression in human lung cancer cell lines
Immunoblot analyses of a panel of human lung cancer cell
lines demonstrated that in basal conditions NSCLC cells show
higher expression level of p120 RasGAP compared with SCLC
cells (Figure 1A and B). These results are based partially on
the fact that SCLC cell lines displayed increased processing of
the full-length RasGAP protein into the N-terminal RasGAP
fragment. As summarized in Table I, SCLC cells are charac-
terized by an elevated level of spontaneous apoptosis as esti-
mated by nuclear DNA fragmentation. While 9  2% of
apoptotic cells have been identified in SCLC cell lines,
NSCLC cell lines showed nuclear features of apoptosis in
51% of cells (P 5 0.01 versus SCLC). Subsequent linear
regression analysis revealed a significant, positive correlation
between the number of cells with spontaneous apoptosis and
the relative cleavage of fragment N per RasGAP in human
lung carcinomas (Figure 1C).
Cell death and caspase activation induced by ET in SCLC and
NSCLC
Two human lung cancer cell lines with different levels of
spontaneous apoptosis and initial formation of RasGAP frag-
ment N were selected from the whole panel and investigated in
detail: U1810 as an example for NSCLC and H82 for SCLC
(Table I). Both cell lines were subjected to treatment with
increasing concentrations of ET (2.5--10 mM) for 48 h. In
addition the broad-spectrum protein kinase inhibitor ST
(1 mM, 2--6 h) and the agonistic aFas antibody (200 ng/ml,
24 h) have been used to induce cell death (see below).
Figure 2 demonstrates that treatment of U1810 and H82 cells
with ET resulted in a G2/M phase cell cycle arrest with a strong
tendency of U1810 cells to accumulate already in the S phase
at higher concentrations (5 mM) of ET. The characterization
of cell death triggered by ET and its influence by simultaneous
inhibition of caspases using the broad-range inhibitory peptide
zVAD-FMK (20 mM) is summarized in Table II. Taken
together, these investigations revealed that loss of the plasma
membrane integrity is a main feature of NSCLC U1810 cells
undergoing ET-induced death, while the presence of apoptotic
nuclei and subG1 DNA fragmentation are less prominent.
However, a certain amount of U1810 was also characterized
by typical apoptotic changes such as nuclear condensation,
formation of membrane blebbing and cell shrinkage without
trypan blue uptake (Figure 2B). The inhibition of caspases by
zVAD-FMK did not prevent ET-induced apoptosis in U1810
cells. Rather it slightly shifted U1810 cells towards features of
necrosis as shown by an increased leakage of the plasma
membrane (Table II). In contrast to U1810, SCLC H82 cells
underwent a type of cell death more typical for apoptosis,
which could be diminished following caspase inhibition by
zVAD-FMK (Table II, Figure 2B). In response to 5 mM ET,
the amount of cells with apoptotic nuclear morphology and
hypoploidy, as well as the number of trypan blue-positive cells
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Fig. 1. (A) Detection and (B) quantification of RasGAP and RasGAP fragment N by immunoblotting in a panel of human lung cancer cell lines from NSCLC and
SCLC. Given data are means  SEM. (C) Linear regression analysis demonstrates a significant, positive correlation between relative cleavage of fragment
N per RasGAP and spontaneous apoptotic DNA fragmentation in lung carcinoma cell lines (n  12; r, linear regression coefficient).
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Table I. Expression and cleavage of RasGAP in a panel of untreated human lung cancer cell lines
Lung cancer cell line Histology Mean RasGAP
proteina
Mean ratio fragment
N per RasGAPb
Spontaneous apoptosis
(% cells)c
H69 SCLC 0.40 1.36 8
H592 SCLC 0.61 0.87 4
H82 SCLC 0.73 0.72 4
U1690 SCLC 0.71 0.72 10
U1285dox SCLC 0.61 1.50 15
U1285 SCLC 0.56 0.99 10
A549 NSCLC, ACa 0.77 0.65 0.5
H23 NSCLC, ACa 0.87 0.71 1
H125 NSCLC, ACa 1.21 0.48 n.d.
H157 NSCLC, LCa 0.93 0.76 1
H661 NSCLC, LCa 2.12 0.69 n.d.
U1810 NSCLC, LCa 2.32 0.37 0.5
U1752 NSCLC, SSCa 0.71 0.46 1
ACa, adenocarcinoma; LCa, large cell carcinoma; SCCa, squamous cell carcinoma; n.d., not determined.
aProtein level for RasGAP is given as densitometrically determined value in relation to GAPDH.
bRatio of RasGAP fragment N per full-length RasGAP. Samples from two different passages (passage 2 and 5) were analysed.
cSpontaneous apoptosis index is calculated from percentages of cells with subG1 DNA fragmentation and TUNEL-positive nuclei.
Fig. 2. (A) DNA staining of U1810 and H82 cells with propidium iodide and subsequent cell cycle analysis by cytometry after treatment with 5 mM ET (48 h).
Arrows indicate aneuploid subpopulations (A,a) of U1810 cells in S phase. (B) Light microscopy of trypan blue-stained U1810 and H82 cells stimulated with
ET as indicated. (C) The presence of pro-caspases and their proteolytically activated subunits (p) in cells stimulated with the indicated concentrations of ET for
48 h was analysed by western blot using total protein lysate (35 mg). The release of cytochrome c was analysed by western blot using cytosolic fraction
(50 mg). (D) Detection of cytochrome c in cytosolic preparations of HeLa cells (50 mg) after ET treatment with and without zVAD-FMK (20 mM) in
comparison with ST (4 h). GAPDH immunostaining indicates the same protein loading.
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and the extent of cytochrome c release, were clearly reduced in
H82 cells treated with zVAD-FMK (Table II). At higher con-
centration of ET (10 mM), zVAD-FMK still mediated the
inhibition of both the formation of the subG1 peak and loss
of cell viability, but the inhibition of cytochrome c release was
nearly abolished (Table II).
Although U1810 cells displayed some necrotic features in
response to ET treatment, these cells exhibited a high DEVD-
proteolytic activity of caspase-3-like proteases compared with
H82 cells (Figure 3). Caspase-9 was similarly activated in both
lung carcinoma cell lines as measured by LEHD-AMC pro-
teolysis (Figure 3). The corresponding cleavage of the pro-
caspase-3 and pro-caspase-9 was also detected clearly along
with the mitochondrial release of cytochrome c (Figure 2C).
Furthermore, treatment of U1810 cells with ET resulted in the
cleavage of pro-caspase-8, which is not expressed in most
SCLC cell lines including H82 (Figure 2C).
It has been shown previously that the typical for apoptotic
nuclear changes (e.g. DNA ladder formation) are less prom-
inent in NSCLC cell lines because of the failure of caspase-3 to
re-localize to the nucleus (26). Therefore, HeLa cells were
analysed as a non-lung carcinoma cell line for comparison.
In contrast to U1810 cells, HeLa cells display nuclear localiza-
tion of active caspase-3 in response to ET despite a relative
resistance towards the drug (27,28). In untreated conditions,
the percentage of cells with apoptotic nuclei was comparable
for HeLa and U1810 cells, but there were less HeLa cells
taking up trypan blue compared with either U1810 or H82
cells (Table II). The amount of HeLa cells with spontaneous
apoptosis correlated with the initial cleavage of RasGAP into
fragment N (Figure 1C). Although the ET-induced death of
HeLa cells was characterized by clear apoptotic morphology
and plasma membrane leakage that could be reduced by
zVAD-FMK (Table II), unchallenged HeLa cells released
more mitochondrial cytochrome c in response to the caspase
inhibitor (Figure 2D, compare the first two lanes), indicating
that certain caspase-independent cell death pathways can be
activated in these cells.
Spontaneous and ET-induced processing of RasGAP in lung
cancer
Total protein preparations as well as cytosolic subfractions
were used for the detection of RasGAP and its caspase-
generated proteolytic fragments. To compare the cleavage of
RasGAP with another caspase substrate, cleavage of PARP
was also investigated.
The generation of the N-terminal RasGAP fragment already
occurs in the presence of low caspase activities (8). However,
in vitro cell culturing entails several factors of stress that might
influence the initial cleavage of RasGAP into fragment N.
Therefore, the level of spontaneously generated RasGAP frag-
ment N has been observed throughout all experiments per-
formed with U1810, H82 and HeLa cells. The range of the
relative amount of fragment N per RasGAP was found to be
comprised between 0.1 and 0.5 for U1810, between 0.25 and
1.0 for H82 and between 0.25 and 1.2 for HeLa cells. The
mean ratios of fragment N per full-length RasGAP are sum-
marized in Figure 4 in comparison with the spontaneous cell
death determined for each cell line. This revealed a positive
correlation between relative fragment N generation and the
amount of apoptotic cells but an inverse tendency to the
amount of cells with necrotic morphology.
In order to evaluate a relationship between the formation of
anti-apoptotic RasGAP fragment N and the susceptibility of
lung cancer cells to apoptosis, cells were treated with different
concentrations of ET (2.5--10 mM) for 48 h. Protein separation
(total cellular proteins or cytosolic preparations) revealed that,
in contrast to full-length RasGAP and fragment N2, the
Table II. Characterization of cell death induced by ET and its influence by concomitant broad-range inhibition of caspases using zVAD-FMK
Cell line ET treatment, 48 h Apoptotic nuclei (%)a SubG1 DNA
content (%)b
Cell viability
loss (%)c
Cytosolic
cytochrome c (%)d
Mean fragmented Mean condensed Both features
U1810 Control 0.6 1.8 2.3  0.6 0.5  0.2 4.9  0.9 1.2  0.3
2.5 mM 3.1 5.3 8.5  1.1 2.6  0.8 13  2.8 8.0  1.6
5.0 mM 3.3 8.9 11  1.4 2.9  0.5 16  1.6 13  2.1
5.0 mM  zVAD-FMK n.d. n.d. n.d. 2.7  0.4 26  5.5 18  3.0
10 mM 2.7 10 13  2.3 3.9  1.2 24  2.7 21  6.0
10 mM  zVAD-FMK 2.8 10 13  3.1 3.0  0.4e 26  4.2 22  8.6
H82 Control 2.1 1.5 3.6  0.6 2.2  0.6 4.0  0.6 8.6  3.4
2.5 mM 4.6 4.3 8.9  1.7 4.6  1.2 11  1.4 14  4.0
5.0 mM 9.1 4.3 13  0.9 6.2  1.4 14  1.1 21  5.4
5.0 mM  zVAD-FMK n.d. n.d. n.d. 4.2  1.0e 10  2.6e 13  4.9e
10 mM 15 6.9 22  3.3 7.5  2.2 19  2.1 21  5.3
10 mM  zVAD-FMK 5.2 6.1 11  1.7e 4.7  1.7e 13  3.1e 19  6.2
HeLa Control 1.1 1.4 2.5  0.6 1.8  0.7 1.6  0.4 3.7  1.1
2.5 mM 4.8 8.8 14  4.2 2.3  0.3 8.9  2.0 12  4.0
5.0 mM 5.7 10 16  2.9 2.4  0.4 16  2.7 15  5.2
5.0 mM  zVAD-FMK n.d. n.d. n.d. 1.9  0.2e 7.0  1.0e 42  5.8e
10 mM 5.1 11 16  2.0 2.4  0.4 19  2.8 22  6.5
10 mM  zVAD-FMK 3.1 7.3 10  0.6e 1.8  0.4e 16  2.3e 46  13e
n.d., not determined.
aPercentage of cells with apoptotic morphology as determined by Hoechst 33342 staining and microscopy.
bDNA hypoploidy measured by cytometry.
cTrypan blue uptake.
dDensitometry of immunoblot analysis for cytosolic level of cytochrome c per total amount, which was determined in presence of Triton X-100 and set to
100%. Data are given as mean  SEM with n  5, n  3 (zVAD-FMK, 20 mM).
eP 5 0.05 versus ET treatment at the same concentration without zVAD-FMK.
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RasGAP fragment N is not localized within the cytosol
(Figure 5A). Confirming the results presented in Figure 1B,
immunoblot analyses demonstrated that RasGAP is always
expressed at the highest protein level in NSCLC U1810 cells
and that the relative cleavage of RasGAP into fragment N in
these cells is less induced than in H82 and HeLa cells. Gen-
eration of fragment N augmented in HeLa cells in response to
increasing concentrations of ET (5--10 mM) (Figure 5A). This
was not observed in both lung cancer cell lines.
As shown representatively on Figure 5A (left panel) ET
induced the final cleavage of fragment N with formation of
the pro-apoptotic RasGAP fragment N2 in NSCLC U1810
cells. This is in accordance with the elevated DEVD-
proteolytic activity detected in U1810 cells, either directly in
cell lysates (Figure 3) or indirectly by the assessment of PARP
cleavage (Figure 5B). The caspase-mediated cleavage of Ras-
GAP into fragment N2 was strongly reduced by broad-range
inhibition of caspases using zVAD-FMK (Figure 5A, left
panel). However, pan-caspase inhibitor zVAD-FMK did not
influence the generation of RasGAP fragment N (Figure 5A,
right panel).
Comparison of RasGAP cleavage mediated by treatment with
ET, ST or aFas
There was similar proteolytic activity of caspase-3-like pro-
teases induced in H82 and U1810 cells by a 48-h treatment
with ET or a 4-h exposure to ST (Figure 3). In contrast, ST
induced a much stronger caspase-3-like activity in HeLa cells
compared with ET, consistent with the observation that these
cells underwent massive apoptosis in response to ST (91 1%
of apoptotic nuclei; n  4). ST is known to trigger cell death
effectively in all lung carcinomas (26), and treatment with this
compound caused appearance of 27  2% of apoptotic nuclei
in U1810 and 40  2% in H82 cells. In accordance with
differences in caspase activation, ST induced the cleavage of
RasGAP into the N- and C-terminal fragments more efficiently
than ET (Figures 5A and 7A). The agonistic aFas antibody
induced even less RasGAP processing into fragment N2 than
ET in U1810 cells (Figure 6). No generation of fragment N2
could be detected in H82 cells treated with the aFas antibody
(Figure 6), as expected as these cells lack pro-caspase-8
(Figure 2). In contrast to both lung carcinoma cell lines, Fas
activation readily caused the cleavage of RasGAP into frag-
ment N2 in HeLa and in Jurkat cells. This cleavage event was
decreased by inhibition of caspase-3/-7 with DEVD-FMK and
totally prevented by inhibition of caspase-8 using IETD-FMK
(Figure 6).
Analysis of total protein preparations and cytosolic subfrac-
tions revealed that RasGAP fragment N, in contrast to the full-
length RasGAP protein, displayed a non-cytosolic location
(Figures 5A and 7A and B). However, partial localization of
fragment N in the cytosol fraction could be detected in certain
conditions. Indeed, cytosolic detection of RasGAP fragment
N has been observed after severe cell death induction by ST
(Figure 7A) and after ET-induced cell death with the con-
comitant inhibition of caspases in U1810 and HeLa cells
(Figure 7B). Since the cleavage into fragment N2 was clearly
reduced by zVAD-FMK, a possible explanation for the cyto-
solic detection of fragment N could be that cell death occurs
along with the degradation of intracellular organelles, includ-
ing nuclear disintegration or swelling and rupture of mito-
chondria. Consistent with this possibility is our observation
Fig. 3. Proteolytic caspase activity for caspase-3/-7 (above) and caspase-9 (below) after treatment of U1810, H82 and HeLa cells with increasing concentrations of
ET (48 h) or with ST (4 h). White bars indicate concomitant incubation with the pan-caspase inhibitory peptide zVAD-FMK. All data are means  SEM (n  5).
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that PARP, which is excluded from the cytosolic subfraction in
control conditions, translocates to this particular fraction upon
stimulation with either ET in the presence of caspase inhibitor
or in the presence of ST (Figure 7C).
Discussion
The family of p21 Ras proteins represents key components in
the cellular signal transduction cascade leading to cell growth
and differentiation. Function of p21 Ras family members has
been linked to various processes that are important for cancer
cell mutagenesis and metastasis (29). The regulation of Ras
activity involves conversion of the inactive Ras-GDP to active
Ras-GTP form in which RasGAPs contribute to the down-
regulation of Ras by accelerating GTP hydrolysis of activated
Ras. Five mammalian GAPs for Ras have been described
including p120 RasGAP, the main GAP for this class of pro-
teins (30). In this study, we have demonstrated that RasGAP
is differentially expressed in SCLC and NSCLC cells. While
NSCLC cell lines showed a strong expression of RasGAP
protein, the mean RasGAP level was markedly decreased in
SCLC cells. Previous studies already revealed a putative role
for RasGAP in tumorigenesis. Although data for GAPs are rare
in human lung neoplasm, the oncogenic potential of RasGAP
due to mutations within the SH2 region are demonstrated in
other malignancies, as well as nuclear re-localization and
alterations in the gene expression (24,31). In this regard, an
inverse correlation between the level of RasGAP and the
invasive potential and malignant phenotype has been described
(32,33). Based on the poor clinical prognosis of SCLC (18),
our data additionally imply that low expression of RasGAP
is associated with tumorigenesis and aggressive growth of
SCLC. However, reduced availability of RasGAP could trig-
ger two independent mechanisms. On one hand, it may be
associated with the malignant behaviour of tumour cells, but,
on the other hand, it may promote apoptotic cell death. In this
context, Leblanc et al. revealed that RasGAP inhibition spe-
cifically induces apoptosis in tumour cells (34), an observation
that could be related to the fact that SCLC display low levels of
RasGAP and are characterized by relatively high level of
spontaneous apoptosis (35). Furthermore, RasGAP deficiency
also leads to neuronal cell death during embryonic develop-
ment (36). In contrast to SCLC, RasGAP is well expressed in
NSCLC suggesting that its main action in these cells is to act
as a negative regulator of Ras activity. Nevertheless, one has to
keep in mind that in contrast to SCLC, NSCLC often bear
oncogenic mutations in the ras genes (29) that render the Ras
proteins insensitive to RasGAP (37).
RasGAP is a dual function protein in the Ras signalling
pathway because it also participates positively in cell signal-
ling by mediating protein--protein interactions downstream
of Ras- and Rho-dependent pathways (7,38). In the apoptotic
process, the complex network of intracellular interactions via
several protein domains in RasGAP is still intact despite its
processing by caspases into several fragments. All generated
forms of RasGAP have functional activity contributing to cell
survival as well as to apoptosis (8). While the N-terminal
cleavage product of RasGAP of the first cleavage event (frag-
ment N) has anti-apoptotic property, the resulting C-terminal
fragment as well as both N-terminal fragments (N1 and N2),
generated due to the second cleavage event of fragment N,
potentiate apoptosis. Analysis of a panel of human lung
cancer cell lines revealed differential levels of RasGAP
expression in NSCLC and SCLC, partially as a consequence
of increased spontaneous RasGAP cleavage in SCLC cell lines
compared with NSCLC cell lines. This primary processing of
RasGAP into fragment N correlated with the higher level of
spontaneous apoptosis in SCLC, an observation that might
explain the initial RasGAP cleavage in the absence of apoptotic
stimulus. Although RasGAP fragment N can protect cells
via PI-3 kinase/Akt signalling (10), it may in some circum-
stances promote apoptosis in a Rho-dependent manner (34).
Therefore and because of the parallel generation of the
Fig. 4. Mean cleavage of full-length RasGAP into fragment N in U1810,
H82 and HeLa cells. These results are derived from untreated controls of all
experiments performed with ET, ST or aFas (n  8). Multiple comparison
by ANOVA procedure revealed a statistically significant difference among
the groups as indicated (P 5 0.05). Ratio of fragment N per RasGAP is
shown in comparison with spontaneous cell death values for nuclear
apoptosis (subG1 DNA fragmentation) and cell viability staining (trypan blue
uptake).
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Fig. 5. (A) The presence of RasGAP and its N-terminal cleavage products was analysed by western blot in total protein lysate (50 mg) and cytosolic fraction
(25 mg) from U1810, H82 and HeLa cells treated with different concentrations of ET (48 h) or with ST (4 h). zVAD-FMK (20 mM) was used to inhibit
caspase activity. The cytosolic fraction contained RasGAP and fragment N2 but lacked fragment N. (B) The corresponding cleavage of PARP into fragment
p85 was also analysed by western blot in total protein lysates.
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pro-apoptotic RasGAP fragment C, it is unclear if fragment N
signalling is predominant in the molecular switch of SCLC
cells. However, survival pathways initiated by RasGAP frag-
ment N did overcome the opposite function of fragment C
in vitro (8) and may participate in the constitutive activation
of the Akt kinase observed in SCLC (39) and in the malignant
phenotype of SCLC. The constitutive Akt stimulation has been
shown to contribute to the transition of chemo- and radio-
sensitive SCLC cells to therapy-resistant tumours and trans-
formation of classic (c-) SCLC to the insensitive variant (v-)
SCLC (39). Although Akt is also activated in response to many
growth factors (IGF-I, EGF, bFGF and others) and active Akt
kinase has been shown in nearly 70% of patients with NSCLC
as well (40), fragment N-mediated signalling represents an
additional survival pathway in SCLC independent of the
growth factor administration. Furthermore, we have revealed
that RasGAP fragment N is not detectable in the cytosol
whereas p120 RasGAP is. These findings raise the possibility
that RasGAP proteins located at the plasma membrane and in
other intracellular membranes are more accessible to proteo-
lysis by caspases. Therefore, processing of RasGAP into frag-
ment N would occur where RasGAP is actively regulating cell
signalling. Alternatively, once formed, fragment N may imme-
diately be targeted to non-cytosolic structures. There are pecu-
liar cases, however, where fragment N is detected in the
cytosolic fraction. For example, when caspases are inhibited
in U1810 cells subjected to ET stimulation, a treatment that
shifts the cells towards necrosis, fragment N and also PARP
are detected in the cytosol. The increased generation of Ras-
GAP fragment N might be one protective factor, especially in
HeLa cells, that contributes to cell survival despite of intracel-
lular necrotic changes.
The serine/threonine kinase Akt is phosphorylated and acti-
vated in response to apoptotic signals mediated by treatment of
lung cancer cells with anticancer agents like ET (41). In our
study we have demonstrated that generation of the Akt-stimu-
lating RasGAP fragment N occurs after treatment of NSCLC
and SCLC cells with ET as well. The formation of fragment N
was relatively stable despite increasing concentrations of ET
and always clearly detectable even with concomitant action of
caspase-inhibitory peptides. This suggests a certain baseline
proteolytic activity of caspases, which can be reduced but not
completely abolished by action of peptide inhibitors. This
observation furthermore indicates the high susceptibility of
RasGAP for caspase proteolysis at its first cleavage site.
In contrast to the first cleavage of RasGAP into fragment N,
the second cleavage of RasGAP fragment N into fragment N2
depends on the increased caspase activity in NSCLC and
SCLC cell lines. While the activity of caspase-3-like proteases
is high in NSCLC U1810 cells that readily generate RasGAP
fragment N2, SCLC H82 cells did not display such a high
proteolytic activity and were less able to produce fragment
N2. Consistent with the notion that caspase-3 activity is
required for the generation of fragment N2 is the observation
that HeLa cells induce high level of caspase-3-like activity in
response to ST and efficiently process RasGAP into fragment
N2. In contrast to caspase-3-like proteases, a direct relation-
ship between caspase-9 activity and terminal cleavage of Ras-
GAP could not be drawn. The proteolytic rate of caspase-9 was
low in comparison with caspase-3-like proteases in conditions
where RasGAP was efficiently cleaved. One possible explana-
tion for the differential activation of caspases could be that the
continuous generation of RasGAP fragment N contributes, via
PI-3 kinase/Akt stimulation, to phosphorylation and inactiva-
tion of caspase-9 (14).
In comparison with ET, the cell death-inducing effect of ST
is more powerful although the anti-apoptotic RasGAP frag-
ment N was generated as well. This might not only be based on
the second cleavage event, transformation of fragment N into
the pro-apoptotic fragment N2, but also on the fact that ST
inhibits numerous kinases including PDK1 (42), which are
required for the entire Akt function (11). Moreover, treatment
with ST rapidly induces mitochondrial dysfunction in tumour
cells (26) that might additionally overcome the protective
effect of RasGAP fragment N.
Recent studies have shown that stimulation of the PI-3
kinase/Akt pathway precedes the onset of apoptosis and cleav-
age of PARP upon treatment with ET (41). The clear formation
of RasGAP fragment N in all cell lines studied and its further
generation in response to ET might be one component con-
tributing to cell survival via PI-3 kinase/Akt signalling and
modulation of apoptosis. Although a potent anti-apoptotic
effect has been described for RasGAP fragment N (8) and
the Akt kinase pathways in general (22,23,39), it is difficult
to set the level of RasGAP fragment N detected in NSCLC and
SCLC into direct relation with the level of spontaneous and
ET-induced apoptosis. There are several important factors that
might impair the protective effect of the N-terminal RasGAP
fragment and subsequently change the apoptotic phenotype.
First, SCLC cell lines express lower levels of RasGAP protein
Fig. 6. Detection of RasGAP fragment N2 by western blot in U1810, H82 and HeLa cells treated for 24 h with the agonistic aFas antibody (Fas, 200 ng/ml), in
U1810 cells subjected to a high-dose of ET (25 mM) for 24 h and in Jurkat cells stimulated with the aFas antibody for the indicated periods of time. Caspase
inhibitors (zDEVD-FMK and zIETD-FMK at 20 mM) were added where indicated.
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Fig. 7. The indicated cell lines were incubated with ST (1 mM) (A and C) or ET at the indicated concentrations (ET, 48 h) in the absence or in the presence of
zVAD-FMK (20 mM) (B and C). The presence of RasGAP and its cleavage fragments (fragments N, N2 and C) (upper two panels), and PARP and its
cleavage fragment (bottom panel) were visualized by western blot.
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compared with NSCLC. Consequently, the amount of frag-
ment N generated by caspases is reduced despite higher levels
of RasGAP processing. Secondly, strong stimulation of cas-
pases in response to chemotherapeutic agents results in the
simultaneous formation of RasGAP fragments (N1, N2 and C)
that have the ability to potentiate apoptosis (8). This could
differentially affect the apoptotic responses in cells that do not
activate caspases to the same extent, as observed in NSCLC
and SCLC. Thirdly, Akt, the target anti-apoptotic kinase of the
RasGAP fragment N pathway, is itself a caspase substrate (43).
Consequently an equilibrium between apoptotic and survival
signals may rapidly be off-balanced by the negative cross-talks
occurring between Akt and the caspases. Fourthly, the caspase-
mediated cleavage of RasGAP reduces p120 RasGAP levels
and this may weaken the negative regulation of p21 Ras
proteins and consequently favour the development of malig-
nant neoplasm (7,29,34). Fifthly, lung cancer cell lines are
characterized by several defects in the apoptotic machinery,
like the inefficient translocation of key caspases, i.e. active
caspase-3, into the nucleus in NSCLC (21) or the defective
expression of caspase-8 in SCLC (44). The insensitivity of
lung cancer cells to Fas receptor stimulation correlated with
the restricted cleavage of RasGAP into fragment N2.
Our findings indicate that spontaneous RasGAP cleavage
into fragment N at low caspase activity and the reduced level
of p120 RasGAP are associated with higher spontaneous apop-
tosis in SCLC compared with NSCLC. The anti-apoptotic
fragment N might also contribute to the highly malignant and
terminally therapy-resistant phenotype of SCLC. In response
to ET and induction of higher caspase activity, lung cancer
cells stably generate RasGAP fragment N, which does have the
potential to impair the complex network of apoptosis. How-
ever, compensatory mechanisms triggered by treatment with
ET and distinct failures in the apoptotic machinery of lung
cancer cells can differently influence the protective effect of
the N-terminal RasGAP fragment in NSCLC and SCLC.
Acknowledgements
This work was supported by grants (to B.Z.) from the Swedish (3829-B02-
07XBC) and Stockholm (03:173) Cancer Societies, EC-RTD grant (QLK3-
CT-2002--01956), by a fellowship for B.B. from the Institute of Environmental
Medicine, Karolinska Institutet, and by grants (to C.W.) from the Oncosuisse
(OCS 1110-02-2001) and from the Swiss National Science Foundation (3100-
066797/1).
References
1.Geenlee,R., Hill-Harmon,M., Murray,T. and Thun,M. (2001) Cancer
statistics, 2001. CA Cancer J. Clin., 51, 15--36.
2.Li,T.K. and Liu,L.F. (2001) Tumor cell death induced by topoisomerase-
targeting drugs. Annu. Rev. Pharmacol. Toxicol., 41, 53--77.
3.Ferraro,C., Quemeneur,L., Fournel,S., Prigent,A.F., Revillard,J.P. and
Bonnefoy-Berard,N. (2000) The topoisomerase inhibitors camptothecin
and etoposide induce a CD95- independent apoptosis of activated
peripheral lymphocytes. Cell Death Differ., 7, 197--206.
4.Thornberry,N.A. and Lazebnik,Y. (1998) Caspases: enemies within.
Science, 281, 1312--1316.
5.Hengartner,M.O. (2000) The biochemistry of apoptosis. Nature, 407,
770--776.
6.Earnshaw,W., Martins,L. and Kaufmann,S. (1999) Mammalian caspases:
structure, activation, substrates and functions during apoptosis. Annu. Rev.
Biochem., 68, 383--424.
7.Donovan,S., Shannon,K.M. and Bollag,G. (2002) GTPase activating
proteins: critical regulators of intracellular signaling. Biochim. Biophys.
Acta, 1602, 23--45.
8. Yang,J.Y. and Widmann,C. (2001) Antiapoptotic signaling generated by
caspase-induced cleavage of RasGAP. Mol. Cell. Biol., 21, 5346--5358.
9. Pomerance,M., Thang,N., Tocque,B. and Pierre,M. (1996) The Ras-
GTPase-activating protein SH3 domain is required for Cdc2 activation
and mos induction by oncogenic Ras in Xenopus oocytes independently
of mitogen-activated protein kinase activation. Mol. Biol. Cell, 16,
3179--3186.
10.Yang,J.Y. and Widmann,C. (2002) The RasGAP N-terminal fragment
generated by caspase cleavage protects cells in a Ras/PI3K/Akt-dependent
manner that does not rely on NFkappa B activation. J. Biol. Chem., 277,
14641--14646.
11.Vanhaesebroeck,B. and Alessi,D. (2000) The PI3K-PDK1 connection:
more than just a road to PKB. Biochem. J., 346, 561--576.
12.Datta,S.R., Dudek,H., Tao,X., Masters,S., Fu,H., Gotoh,Y. and
Greenberg,M.E. (1997) Akt phosphorylation of BAD couples survival
signals to the cell-intrinsic death machinery. Cell, 91, 231--241.
13.Tsuruta,F., Masuyama,N. and Gotoh,Y. (2002) The phosphatidylinositol
3-kinase (PIP3K)-Akt pathway suppresses Bax translocation to mitochon-
dria. J. Biol. Chem., 277, 14040--14047.
14.Cardone,M.H., Roy,N., Stennicke,H.R., Salvesen,G.S., Franke,T.F.,
Stanbridge,E., Frisch,S. and Reed,J.C. (1998) Regulation of cell death
protease caspase-9 by phosphorylation. Science, 282, 1318--1321.
15.Romashkova,J. and Makarov,S. (1999) NF-kappaB is a target of AKT in
anti-apoptotic PDGF signalling. Nature, 401, 86--90.
16.Travis,W., Colby,R., Corrin,B., Shimosato,Y., Brambilla,E., in collabora-
tion with Sobin,L.H. and pathologists from 14 countries (1999) WHO
International Classification of Tumours. Histological Typing of Lung and
Pleural Tumours. Springer, Berlin.
17.Sekido,Y., Fong,K. and Minna,J. (1998) Progress in understanding the
molecular pathogenesis of human lung cancer. Biochim. Biophys. Acta,
1378, F21--F59.
18.Comis,R., Friedland,D. and Good,B. (1998) Small-cell lung cancer: a
perspective on the past and a preview of the future. Oncology, 12, 44--50.
19.Beck,W.T., Morgan,S.E., Mo,Y.Y. and Bhat,U.G. (1999) Tumor cell
resistance to DNA topoisomerase II inhibitors: new developments. Drug
Resist. Updat., 2, 382--389.
20. Joseph,B., Lewensohn,R. and Zhivotovsky,B. (2000) Role of apoptosis in
the response of lung carcinomas to anti-cancer treatment. Ann. N. Y. Acad.
Sci., 926, 204--216.
21. Joseph,B., Ekedahl,J., Lewensohn,R., Marchetti,P., Formstecher,P. and
Zhivotovsky,B. (2001) Defective caspase-3 relocalization in non-small
cell lung carcinoma. Oncogene, 20, 2877--2888.
22.Brognard,J., Clark,A., Ni,Y. and Dennis,P. (2001) Akt/protein kinase B is
constitutively active in non-small cell lung cancer cells and promotes
cellular survival and resistance to chemotherapy and radiation. Cancer
Res., 61, 3986--3997.
23.Krystal,G., Sulanke,G. and Litz,J. (2002) Inhibition of phosphatidylino-
sitol 3-kinase-Akt signaling blocks growth, promotes apoptosis and
enhances sensitivity of small cell lung cancer cells to chemotherapy.
Mol. Cancer Ther., 1, 913--922.
24.Friedman,E. (1995) The role of ras GTPase activating protein in human
tumorigenesis. Pathobiology, 63, 348--350.
25.Ekedahl,J., Joseph,B., Grigoriev,M.Y., Muller,M., Magnusson,C.,
Lewensohn,R. and Zhivotovsky,B. (2002) Expression of inhibitor of
apoptosis proteins in small- and non-small-cell lung carcinoma cells. Exp.
Cell Res., 279, 277--290.
26. Joseph,B., Marchetti,P., Formstecher,P., Kroemer,G., Lewensohn,R. and
Zhivotovsky,B. (2002) Mitochondrial dysfunction is an essential step for
killing of non-small cell lung carcinomas resistant to conventional
treatment. Oncogene, 21, 65--77.
27.Susin,S.A., Daugas,E., Ravagnan,L. et al. (2000) Two distinct pathways
leading to nuclear apoptosis. J. Exp. Med., 192, 571--580.
28.Heenan,M., Kavanagh,K., Redmond,A., Maher,M., Dolan,E., O'Neill,P.,
Moriarty,M. and Clynes,M. (1996) Absence of correlation between
chemo- and radioresistance in a range of human tumour cell lines.
Cytotechnology, 19, 237--242.
29. Iyengar,P. and Tsao,M.-S. (2002) Clinical relevance of molecular markers
in lung cancer. Surg. Oncol., 11, 167--179.
30.Scheffzek,K., Lautwein,A., Scherer,A., Franken,S. and Wittinghofer,A.
(1997) Crystallization and preliminary X-ray crystallographic study of
the Ras-GTPase-activating domain of human p120GAP. Proteins, 27,
315--318.
31.Davidson,B., Agulansky,L., Goldberg,I., Friedman,E., Ramon,J.,
Barshack,I. and Kopolovic,J. (1998) Immunhistochemical analysis of
rasGTPase activating protein (rasGAP) in prostate cancer. Pathol. Res.
Pract., 194, 399--404.
B.Bartling et al.
920
32.Stahle-Backdhal,M., Inoue,M., Zedenius,J., Sandstedt,B., DeMarco,L.,
Flam,F., Silfversward,C., Andrade,J. and Friedman,E. (1995) Decreased
expression of Ras GTPase activating protein in human trophoblastic
tumors. Am. J. Pathol., 146, 1073--1078.
33.Barshack,I., Goldberg,I., Davidson,B., Ravid,A., Schiby,G., Kopolovic,J.,
Leviav,A. and Friedman,E. (1998) Expression of rasGTPase activa-
ting protein in basal cell carcinoma of the skin. Mod. Pathol., 11,
271--275.
34.Leblanc,V., Delumeau,I. and Tocque,B. (1999) Ras-GTPase activating
protein inhibition specifically induces apoptosis of tumour cells.
Oncogene, 18, 4884--4889.
35.Sirzen,F., Zhivotovsky,B., Nilsson,A., Bergh,J. and Lewensohn,R. (1998)
Higher spontaneous apoptotic index in small cell compared with non-small
cell lung carcinoma cell lines; lack of correlation with Bcl- 2/Bax. Lung
Cancer, 22, 1--13.
36.Henkemeyer,M., Rossi,D., Holmyard,D., Puri,M., Mbamalu,G., Harpal,K.,
Shih,T., Jacks,T. and Pawson,T. (1995) Vascular system defects and
neuronal apoptosis in mice lacking ras GTPase-activating protein. Nature,
377, 695--701.
37.Scheffzek,K., Ahmadian,M., Kabsch,W., Wiesmueller,L., Lautwein,A.,
Schmitz,F. and Wittinghofer,A. (1997) The Ras-RasGAP complex:
structural basis for GTPase activation and its loss in oncogenic Ras
mutants. Science, 277, 333--338.
38.Leblanc,V., Tocque,B. and Delumeau,I. (1998) Ras-GAP controls Rho-
mediated cytoskeletal reorganization through its SH3 domain. Mol. Cell.
Biol., 18, 5567--5578.
39.Kraus,A., Ferber,I., Bachmann,S., Specht,H., Wimmel,A., Gross,M.,
Schlegel,J., Suske,G. and Schuermann,M. (2002) In vitro chemo- and
radio-resistance in small cell lung cancer correlates with cell adhesion and
constitutive activation of AKT and MAP kinase pathways. Oncogene, 21,
8683--8695.
40.Lee,S., Kim,H., Park,W., Kim,S., Lee,K., Kim,S., Lee,J. and Yoo,N.
(2002) Non-small cell lung cancers frequently express phosphorylated
Akt; an immunohistochemical study. Acta Pathol. Microbiol. Immunol.
Scand., 110, 587--592.
41.Tang,D., Okada,H., Ruland,J., Liu,L., Stambolic,V., Mak,T. and
Ingram,A. (2001) Akt is activated in response to an apoptotic signal. J.
Biol. Chem., 276, 30461--30466.
42.Hill,M., Andjelkovic,M., Brazil,D., Ferrari,S., Fabbro,D. and
Hemmings,B. (2001) Insulin-stimulated protein kinase B phosphorylation
on Ser-473 is independent of its activity and occurs through a
staurosporine-insensitive kinase. J. Biol. Chem., 276, 25643--25646.
43.Widmann,C., Gibson,S. and Johnson,G. (1998) Caspase-dependent
cleavage of signaling proteins during apoptosis. A turn-off mechanism for
anti-apoptotic signals. J. Biol. Chem., 273, 7141--7147.
44. Joseph,B., Ekedahl,J., Sirzen,F., Lewensohn,R. and Zhivotovsky,B. (1999)
Differences in expression of pro-caspases in small cell and non-small cell
lung carcinoma. Biochem. Biophys. Res. Commun., 262, 381--387.
Received October 14, 2003; revised December 2, 2003;
accepted December 19, 2003
RasGap cleavage in lung carcinoma
921
